Standard
Liver-related death among HIV/hepatitis C virus-co-infected individuals : Implications for the era of directly acting antivirals. / Grint, Daniel; Peters, Lars; Rockstroh, J.; Rakmanova, Aza; Trofimova, Tatiana; Lacombe, Karine; Karpov, Igor; Galli, Massimo; Domingo, P.; Kirk, Ole; Lundgren, Jens D.; Mocrofta, Amanda; Losso, M.; Kundro, M.; Vetter, N.; Zangerle, R.; Karpov, I.; Vassilenko, A.; Mitsura, V. M.; Paduto, D.; Clumeck, N.; De Wit, S.; Delforge, M.; Florence, E.; Vandekerckhove, L.; Hadziosmanovic, V.; Kostov, K.; Begovac, J.; Machala, L.; Jilich, D.; Sedlacek, D.; Nielsen, J.; Kronborg, G.; Benfield, T.; Larsen, M.; Gerstoft, J.; Katzenstein, T.; Hansen, A. B.E.; Skinhøj, P.; Pedersen, C.; Møller, N. F.; Ostergaard, L.; Dragsted, U. B.; Nielsen, L. N.; Zilmer, K.; Smidt, Jelena; Ristola, M.; Katlama, C.; Viard, J. P.; Girard, P. M.; Vanhems, P.; Pradier, C.; Dabis, F.; Neau, D.; Duvivier, C.; Rockstroh, J.; Schmidt, R.; Van Lunzen, J.; Degen, O.; Stellbrink, H. J.; Stefan, C.; Bogner, J.; Fätkenheuer, G.; Chkhartishvili, N.; Kosmidis, J.; Gargalianos, P.; Xylomenos, G.; Perdios, J.; Sambatakou, H.; Banhegyi, D.; Gottfredsson, M.; Mulcahy, F.; Yust, I.; Turner, D.; Burke, M.; Shahar, E.; Hassoun, G.; Elinav, H.; Haouzi, M.; Sthoeger, Z. M.; Monforte, A. D.arminio; Esposito, R.; Mazeu, I.; Mussini, C.; Pristera, R.; Mazzotta, F.; Gabbuti, A.; Vullo, V.; Lichtner, M.; Zaccarelli, M.; Antinori, A.; Acinapura, R.; D'Offizi, G.; Lazzarin, A.; Castagna, A.; Gianotti, N.; Galli, M.; Ridolfo, A.; Rozentale, B.; Uzdaviniene, V.; Staub, T.; Hemmer, R.; Reiss, P.; Ormaasen, V.; Maeland, A.; Bruun, J.; Knysz, B.; Gasiorowski, J.; Inglot, M.; Horban, A.; Bakowska, E.; Grzeszczuk, A.; Flisiak, R.; Parczewski, M.; Pynka, M.; Maciejewska, K.; Beniowski, M.; Mularska, E.; Smiatacz, T.; Jablonowska, E.; Malolepsza, E.; Wojcik, K.; Mozer-Lisewska, I.; Doroana, M.; Caldeira, L.; Mansinho, K.; Maltez, F.; Radoi, R.; Oprea, C.; Babes, Victor; Rakhmanova, A.; Rakhmanova, A.; Trofimora, T.; Khromova, I.; Kuzovatova, E.; Jevtovic, D.; Shunnar, A.; Staneková, D.; Tomazic, J.; Moreno, S.; Rodriguez, J. M.; Clotet, B.; Jou, A.; Paredes, R.; Tural, C.; Puig, J.; Bravo, I.; Gatell, J. M.; Miró, J. M.; Domingo, P.; Gutierrez, M.; Mateo, G.; Sambeat, M. A.; Laporte, J. M.; Blaxhult, A.; Flamholc, L.; Thalme, A.; Sonnerborg, A.; Ledergerber, B.; Weber, R.; Cavassini, M.; Calmy, A.; Furrer, H.; Battegay, M.; Elzi, L.; Schmid, P.; Kravchenko, E.; Chentsova, N.; Frolov, V.; Kutsyna, G.; Baskakov, I.; Servitskiy, S.; Kuznetsova, A.; Kyselyova, G.; Gazzard, B.; Johnson, M. A.; Simons, E.; Edwards, S.; Phillips, A.; Johnson, M. A.; Mocroft, A.; Orkin, C.; Weber, J.; Scullard, G.; Fisher, M.; Leen, C.
In:
AIDS, Vol. 29, No. 10, 19.06.2015, p. 1205-1215.
Research output: Contribution to journal › Article › peer-review
Harvard
Grint, D, Peters, L, Rockstroh, J, Rakmanova, A
, Trofimova, T, Lacombe, K, Karpov, I, Galli, M, Domingo, P, Kirk, O, Lundgren, JD, Mocrofta, A, Losso, M, Kundro, M, Vetter, N, Zangerle, R
, Karpov, I, Vassilenko, A, Mitsura, VM, Paduto, D, Clumeck, N, De Wit, S, Delforge, M, Florence, E, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Begovac, J, Machala, L, Jilich, D, Sedlacek, D, Nielsen, J, Kronborg, G, Benfield, T, Larsen, M, Gerstoft, J, Katzenstein, T, Hansen, ABE, Skinhøj, P, Pedersen, C, Møller, NF, Ostergaard, L, Dragsted, UB, Nielsen, LN, Zilmer, K, Smidt, J, Ristola, M, Katlama, C, Viard, JP, Girard, PM, Vanhems, P, Pradier, C, Dabis, F, Neau, D, Duvivier, C, Rockstroh, J, Schmidt, R, Van Lunzen, J, Degen, O, Stellbrink, HJ, Stefan, C, Bogner, J, Fätkenheuer, G, Chkhartishvili, N, Kosmidis, J, Gargalianos, P, Xylomenos, G, Perdios, J, Sambatakou, H, Banhegyi, D, Gottfredsson, M, Mulcahy, F, Yust, I, Turner, D, Burke, M, Shahar, E, Hassoun, G, Elinav, H, Haouzi, M, Sthoeger, ZM, Monforte, ADA, Esposito, R, Mazeu, I, Mussini, C, Pristera, R, Mazzotta, F, Gabbuti, A, Vullo, V, Lichtner, M, Zaccarelli, M, Antinori, A, Acinapura, R, D'Offizi, G, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Uzdaviniene, V, Staub, T, Hemmer, R, Reiss, P, Ormaasen, V, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Inglot, M, Horban, A, Bakowska, E, Grzeszczuk, A, Flisiak, R, Parczewski, M, Pynka, M, Maciejewska, K, Beniowski, M, Mularska, E, Smiatacz, T, Jablonowska, E, Malolepsza, E, Wojcik, K, Mozer-Lisewska, I, Doroana, M, Caldeira, L, Mansinho, K, Maltez, F, Radoi, R, Oprea, C, Babes, V
, Rakhmanova, A, Rakhmanova, A, Trofimora, T, Khromova, I, Kuzovatova, E, Jevtovic, D, Shunnar, A, Staneková, D, Tomazic, J, Moreno, S, Rodriguez, JM, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gatell, JM, Miró, JM, Domingo, P, Gutierrez, M, Mateo, G, Sambeat, MA, Laporte, JM, Blaxhult, A, Flamholc, L, Thalme, A, Sonnerborg, A, Ledergerber, B, Weber, R, Cavassini, M, Calmy, A, Furrer, H, Battegay, M, Elzi, L, Schmid, P, Kravchenko, E, Chentsova, N
, Frolov, V, Kutsyna, G, Baskakov, I, Servitskiy, S, Kuznetsova, A, Kyselyova, G, Gazzard, B, Johnson, MA, Simons, E, Edwards, S, Phillips, A, Johnson, MA, Mocroft, A, Orkin, C, Weber, J, Scullard, G, Fisher, M & Leen, C 2015, '
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals',
AIDS, vol. 29, no. 10, pp. 1205-1215.
https://doi.org/10.1097/QAD.0000000000000674APA
Grint, D., Peters, L., Rockstroh, J., Rakmanova, A.
, Trofimova, T., Lacombe, K., Karpov, I., Galli, M., Domingo, P., Kirk, O., Lundgren, J. D., Mocrofta, A., Losso, M., Kundro, M., Vetter, N., Zangerle, R.
, Karpov, I., Vassilenko, A., Mitsura, V. M., ... Leen, C. (2015).
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals.
AIDS,
29(10), 1205-1215.
https://doi.org/10.1097/QAD.0000000000000674Vancouver
Author
Grint, Daniel ; Peters, Lars ; Rockstroh, J. ; Rakmanova, Aza
; Trofimova, Tatiana ; Lacombe, Karine ; Karpov, Igor ; Galli, Massimo ; Domingo, P. ; Kirk, Ole ; Lundgren, Jens D. ; Mocrofta, Amanda ; Losso, M. ; Kundro, M. ; Vetter, N. ; Zangerle, R.
; Karpov, I. ; Vassilenko, A. ; Mitsura, V. M. ; Paduto, D. ; Clumeck, N. ; De Wit, S. ; Delforge, M. ; Florence, E. ; Vandekerckhove, L. ; Hadziosmanovic, V. ; Kostov, K. ; Begovac, J. ; Machala, L. ; Jilich, D. ; Sedlacek, D. ; Nielsen, J. ; Kronborg, G. ; Benfield, T. ; Larsen, M. ; Gerstoft, J. ; Katzenstein, T. ; Hansen, A. B.E. ; Skinhøj, P. ; Pedersen, C. ; Møller, N. F. ; Ostergaard, L. ; Dragsted, U. B. ; Nielsen, L. N. ; Zilmer, K. ; Smidt, Jelena ; Ristola, M. ; Katlama, C. ; Viard, J. P. ; Girard, P. M. ; Vanhems, P. ; Pradier, C. ; Dabis, F. ; Neau, D. ; Duvivier, C. ; Rockstroh, J. ; Schmidt, R. ; Van Lunzen, J. ; Degen, O. ; Stellbrink, H. J. ; Stefan, C. ; Bogner, J. ; Fätkenheuer, G. ; Chkhartishvili, N. ; Kosmidis, J. ; Gargalianos, P. ; Xylomenos, G. ; Perdios, J. ; Sambatakou, H. ; Banhegyi, D. ; Gottfredsson, M. ; Mulcahy, F. ; Yust, I. ; Turner, D. ; Burke, M. ; Shahar, E. ; Hassoun, G. ; Elinav, H. ; Haouzi, M. ; Sthoeger, Z. M. ; Monforte, A. D.arminio ; Esposito, R. ; Mazeu, I. ; Mussini, C. ; Pristera, R. ; Mazzotta, F. ; Gabbuti, A. ; Vullo, V. ; Lichtner, M. ; Zaccarelli, M. ; Antinori, A. ; Acinapura, R. ; D'Offizi, G. ; Lazzarin, A. ; Castagna, A. ; Gianotti, N. ; Galli, M. ; Ridolfo, A. ; Rozentale, B. ; Uzdaviniene, V. ; Staub, T. ; Hemmer, R. ; Reiss, P. ; Ormaasen, V. ; Maeland, A. ; Bruun, J. ; Knysz, B. ; Gasiorowski, J. ; Inglot, M. ; Horban, A. ; Bakowska, E. ; Grzeszczuk, A. ; Flisiak, R. ; Parczewski, M. ; Pynka, M. ; Maciejewska, K. ; Beniowski, M. ; Mularska, E. ; Smiatacz, T. ; Jablonowska, E. ; Malolepsza, E. ; Wojcik, K. ; Mozer-Lisewska, I. ; Doroana, M. ; Caldeira, L. ; Mansinho, K. ; Maltez, F. ; Radoi, R. ; Oprea, C. ; Babes, Victor
; Rakhmanova, A. ; Rakhmanova, A. ; Trofimora, T. ; Khromova, I. ; Kuzovatova, E. ; Jevtovic, D. ; Shunnar, A. ; Staneková, D. ; Tomazic, J. ; Moreno, S. ; Rodriguez, J. M. ; Clotet, B. ; Jou, A. ; Paredes, R. ; Tural, C. ; Puig, J. ; Bravo, I. ; Gatell, J. M. ; Miró, J. M. ; Domingo, P. ; Gutierrez, M. ; Mateo, G. ; Sambeat, M. A. ; Laporte, J. M. ; Blaxhult, A. ; Flamholc, L. ; Thalme, A. ; Sonnerborg, A. ; Ledergerber, B. ; Weber, R. ; Cavassini, M. ; Calmy, A. ; Furrer, H. ; Battegay, M. ; Elzi, L. ; Schmid, P. ; Kravchenko, E. ; Chentsova, N.
; Frolov, V. ; Kutsyna, G. ; Baskakov, I. ; Servitskiy, S. ; Kuznetsova, A. ; Kyselyova, G. ; Gazzard, B. ; Johnson, M. A. ; Simons, E. ; Edwards, S. ; Phillips, A. ; Johnson, M. A. ; Mocroft, A. ; Orkin, C. ; Weber, J. ; Scullard, G. ; Fisher, M. ; Leen, C. /
Liver-related death among HIV/hepatitis C virus-co-infected individuals : Implications for the era of directly acting antivirals. In:
AIDS. 2015 ; Vol. 29, No. 10. pp. 1205-1215.
BibTeX
@article{225f164afdf44e48a27d781660bfdc3d,
title = "Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals",
abstract = "Background: Potent, less toxic, directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection promise to improve HCV cure rates among HIV/ HCV-co-infected individuals. However, the costs of treatment will necessitate prioritization of those at greatest risk of liver-related death (LRD) for therapy. This study aims to provide guidance on who should be prioritized for DAA treatment. Methods: Three thousand, nine hundred and forty-one HCV antibody-positive PSHREG and FIB-4 are names not acronyms (EuroSIDA) patients with follow-up after 1 January 2000 were included, with causes of death classified using Coding causes of Death in HIV (CoDe) methodology. Crude death rates, competing-risks Cox proportional- hazards models and cumulative incidence functions were used to describe factors associated with LRD. Results: LRD accounted for 145 of 670 (21.6%) deaths in the study population. LRD rates peaked in those aged 35'45 years, and occurred almost exclusively in those with at least F2 fibrosis at baseline. In adjustedCoxmodels, risk factors for LRDincluded F4 or F2/F3 fibrosis [sub-distribution hazard ratio (sHR) 6.3, 95%confidence interval (CI)4.1'9.6; andsHR2.5, 95%CI 1.5'4.2 vs. F0/F1, respectively), CD4 cell count (sHR 0.83, 95%CI 0.73'0.95 per doubling) and hepatitis B surface antigen-positive (sHR 2.2, 95% CI 1.3'3.5 vs. hepatitis B surface antigen-negative). The 5-year probability of LRD was low in those with F0/F1 fibrosis (sHR2.2%, 95%CI 1.7''2.9), but substantial in those withF2/F3 and F4 fibrosis (sHR 10.3%, 95% CI 7.6'13.5; and sHR 14.0%, 95% CI 10.3'18.3, respectively). Conclusion: Treatment with DAAs should be prioritized for those with at least F2 fibrosis. Early initiation of cART with the aim of avoiding low CD4 cell counts should be considered essential to decrease the risk of LRD and the need for HCV treatment.",
keywords = "Causes of death, Directly acting antivirals, HIV/HCV co-infection, Liver fibrosis, Liver-related death",
author = "Daniel Grint and Lars Peters and J. Rockstroh and Aza Rakmanova and Tatiana Trofimova and Karine Lacombe and Igor Karpov and Massimo Galli and P. Domingo and Ole Kirk and Lundgren, {Jens D.} and Amanda Mocrofta and M. Losso and M. Kundro and N. Vetter and R. Zangerle and I. Karpov and A. Vassilenko and Mitsura, {V. M.} and D. Paduto and N. Clumeck and {De Wit}, S. and M. Delforge and E. Florence and L. Vandekerckhove and V. Hadziosmanovic and K. Kostov and J. Begovac and L. Machala and D. Jilich and D. Sedlacek and J. Nielsen and G. Kronborg and T. Benfield and M. Larsen and J. Gerstoft and T. Katzenstein and Hansen, {A. B.E.} and P. Skinh{\o}j and C. Pedersen and M{\o}ller, {N. F.} and L. Ostergaard and Dragsted, {U. B.} and Nielsen, {L. N.} and K. Zilmer and Jelena Smidt and M. Ristola and C. Katlama and Viard, {J. P.} and Girard, {P. M.} and P. Vanhems and C. Pradier and F. Dabis and D. Neau and C. Duvivier and J. Rockstroh and R. Schmidt and {Van Lunzen}, J. and O. Degen and Stellbrink, {H. J.} and C. Stefan and J. Bogner and G. F{\"a}tkenheuer and N. Chkhartishvili and J. Kosmidis and P. Gargalianos and G. Xylomenos and J. Perdios and H. Sambatakou and D. Banhegyi and M. Gottfredsson and F. Mulcahy and I. Yust and D. Turner and M. Burke and E. Shahar and G. Hassoun and H. Elinav and M. Haouzi and Sthoeger, {Z. M.} and Monforte, {A. D.arminio} and R. Esposito and I. Mazeu and C. Mussini and R. Pristera and F. Mazzotta and A. Gabbuti and V. Vullo and M. Lichtner and M. Zaccarelli and A. Antinori and R. Acinapura and G. D'Offizi and A. Lazzarin and A. Castagna and N. Gianotti and M. Galli and A. Ridolfo and B. Rozentale and V. Uzdaviniene and T. Staub and R. Hemmer and P. Reiss and V. Ormaasen and A. Maeland and J. Bruun and B. Knysz and J. Gasiorowski and M. Inglot and A. Horban and E. Bakowska and A. Grzeszczuk and R. Flisiak and M. Parczewski and M. Pynka and K. Maciejewska and M. Beniowski and E. Mularska and T. Smiatacz and E. Jablonowska and E. Malolepsza and K. Wojcik and I. Mozer-Lisewska and M. Doroana and L. Caldeira and K. Mansinho and F. Maltez and R. Radoi and C. Oprea and Victor Babes and A. Rakhmanova and A. Rakhmanova and T. Trofimora and I. Khromova and E. Kuzovatova and D. Jevtovic and A. Shunnar and D. Stanekov{\'a} and J. Tomazic and S. Moreno and Rodriguez, {J. M.} and B. Clotet and A. Jou and R. Paredes and C. Tural and J. Puig and I. Bravo and Gatell, {J. M.} and Mir{\'o}, {J. M.} and P. Domingo and M. Gutierrez and G. Mateo and Sambeat, {M. A.} and Laporte, {J. M.} and A. Blaxhult and L. Flamholc and A. Thalme and A. Sonnerborg and B. Ledergerber and R. Weber and M. Cavassini and A. Calmy and H. Furrer and M. Battegay and L. Elzi and P. Schmid and E. Kravchenko and N. Chentsova and V. Frolov and G. Kutsyna and I. Baskakov and S. Servitskiy and A. Kuznetsova and G. Kyselyova and B. Gazzard and Johnson, {M. A.} and E. Simons and S. Edwards and A. Phillips and Johnson, {M. A.} and A. Mocroft and C. Orkin and J. Weber and G. Scullard and M. Fisher and C. Leen",
note = "Publisher Copyright: {\textcopyright} 2015 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2015",
month = jun,
day = "19",
doi = "10.1097/QAD.0000000000000674",
language = "English",
volume = "29",
pages = "1205--1215",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "10",
}
RIS
TY - JOUR
T1 - Liver-related death among HIV/hepatitis C virus-co-infected individuals
T2 - Implications for the era of directly acting antivirals
AU - Grint, Daniel
AU - Peters, Lars
AU - Rockstroh, J.
AU - Rakmanova, Aza
AU - Trofimova, Tatiana
AU - Lacombe, Karine
AU - Karpov, Igor
AU - Galli, Massimo
AU - Domingo, P.
AU - Kirk, Ole
AU - Lundgren, Jens D.
AU - Mocrofta, Amanda
AU - Losso, M.
AU - Kundro, M.
AU - Vetter, N.
AU - Zangerle, R.
AU - Karpov, I.
AU - Vassilenko, A.
AU - Mitsura, V. M.
AU - Paduto, D.
AU - Clumeck, N.
AU - De Wit, S.
AU - Delforge, M.
AU - Florence, E.
AU - Vandekerckhove, L.
AU - Hadziosmanovic, V.
AU - Kostov, K.
AU - Begovac, J.
AU - Machala, L.
AU - Jilich, D.
AU - Sedlacek, D.
AU - Nielsen, J.
AU - Kronborg, G.
AU - Benfield, T.
AU - Larsen, M.
AU - Gerstoft, J.
AU - Katzenstein, T.
AU - Hansen, A. B.E.
AU - Skinhøj, P.
AU - Pedersen, C.
AU - Møller, N. F.
AU - Ostergaard, L.
AU - Dragsted, U. B.
AU - Nielsen, L. N.
AU - Zilmer, K.
AU - Smidt, Jelena
AU - Ristola, M.
AU - Katlama, C.
AU - Viard, J. P.
AU - Girard, P. M.
AU - Vanhems, P.
AU - Pradier, C.
AU - Dabis, F.
AU - Neau, D.
AU - Duvivier, C.
AU - Rockstroh, J.
AU - Schmidt, R.
AU - Van Lunzen, J.
AU - Degen, O.
AU - Stellbrink, H. J.
AU - Stefan, C.
AU - Bogner, J.
AU - Fätkenheuer, G.
AU - Chkhartishvili, N.
AU - Kosmidis, J.
AU - Gargalianos, P.
AU - Xylomenos, G.
AU - Perdios, J.
AU - Sambatakou, H.
AU - Banhegyi, D.
AU - Gottfredsson, M.
AU - Mulcahy, F.
AU - Yust, I.
AU - Turner, D.
AU - Burke, M.
AU - Shahar, E.
AU - Hassoun, G.
AU - Elinav, H.
AU - Haouzi, M.
AU - Sthoeger, Z. M.
AU - Monforte, A. D.arminio
AU - Esposito, R.
AU - Mazeu, I.
AU - Mussini, C.
AU - Pristera, R.
AU - Mazzotta, F.
AU - Gabbuti, A.
AU - Vullo, V.
AU - Lichtner, M.
AU - Zaccarelli, M.
AU - Antinori, A.
AU - Acinapura, R.
AU - D'Offizi, G.
AU - Lazzarin, A.
AU - Castagna, A.
AU - Gianotti, N.
AU - Galli, M.
AU - Ridolfo, A.
AU - Rozentale, B.
AU - Uzdaviniene, V.
AU - Staub, T.
AU - Hemmer, R.
AU - Reiss, P.
AU - Ormaasen, V.
AU - Maeland, A.
AU - Bruun, J.
AU - Knysz, B.
AU - Gasiorowski, J.
AU - Inglot, M.
AU - Horban, A.
AU - Bakowska, E.
AU - Grzeszczuk, A.
AU - Flisiak, R.
AU - Parczewski, M.
AU - Pynka, M.
AU - Maciejewska, K.
AU - Beniowski, M.
AU - Mularska, E.
AU - Smiatacz, T.
AU - Jablonowska, E.
AU - Malolepsza, E.
AU - Wojcik, K.
AU - Mozer-Lisewska, I.
AU - Doroana, M.
AU - Caldeira, L.
AU - Mansinho, K.
AU - Maltez, F.
AU - Radoi, R.
AU - Oprea, C.
AU - Babes, Victor
AU - Rakhmanova, A.
AU - Rakhmanova, A.
AU - Trofimora, T.
AU - Khromova, I.
AU - Kuzovatova, E.
AU - Jevtovic, D.
AU - Shunnar, A.
AU - Staneková, D.
AU - Tomazic, J.
AU - Moreno, S.
AU - Rodriguez, J. M.
AU - Clotet, B.
AU - Jou, A.
AU - Paredes, R.
AU - Tural, C.
AU - Puig, J.
AU - Bravo, I.
AU - Gatell, J. M.
AU - Miró, J. M.
AU - Domingo, P.
AU - Gutierrez, M.
AU - Mateo, G.
AU - Sambeat, M. A.
AU - Laporte, J. M.
AU - Blaxhult, A.
AU - Flamholc, L.
AU - Thalme, A.
AU - Sonnerborg, A.
AU - Ledergerber, B.
AU - Weber, R.
AU - Cavassini, M.
AU - Calmy, A.
AU - Furrer, H.
AU - Battegay, M.
AU - Elzi, L.
AU - Schmid, P.
AU - Kravchenko, E.
AU - Chentsova, N.
AU - Frolov, V.
AU - Kutsyna, G.
AU - Baskakov, I.
AU - Servitskiy, S.
AU - Kuznetsova, A.
AU - Kyselyova, G.
AU - Gazzard, B.
AU - Johnson, M. A.
AU - Simons, E.
AU - Edwards, S.
AU - Phillips, A.
AU - Johnson, M. A.
AU - Mocroft, A.
AU - Orkin, C.
AU - Weber, J.
AU - Scullard, G.
AU - Fisher, M.
AU - Leen, C.
N1 - Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/6/19
Y1 - 2015/6/19
N2 - Background: Potent, less toxic, directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection promise to improve HCV cure rates among HIV/ HCV-co-infected individuals. However, the costs of treatment will necessitate prioritization of those at greatest risk of liver-related death (LRD) for therapy. This study aims to provide guidance on who should be prioritized for DAA treatment. Methods: Three thousand, nine hundred and forty-one HCV antibody-positive PSHREG and FIB-4 are names not acronyms (EuroSIDA) patients with follow-up after 1 January 2000 were included, with causes of death classified using Coding causes of Death in HIV (CoDe) methodology. Crude death rates, competing-risks Cox proportional- hazards models and cumulative incidence functions were used to describe factors associated with LRD. Results: LRD accounted for 145 of 670 (21.6%) deaths in the study population. LRD rates peaked in those aged 35'45 years, and occurred almost exclusively in those with at least F2 fibrosis at baseline. In adjustedCoxmodels, risk factors for LRDincluded F4 or F2/F3 fibrosis [sub-distribution hazard ratio (sHR) 6.3, 95%confidence interval (CI)4.1'9.6; andsHR2.5, 95%CI 1.5'4.2 vs. F0/F1, respectively), CD4 cell count (sHR 0.83, 95%CI 0.73'0.95 per doubling) and hepatitis B surface antigen-positive (sHR 2.2, 95% CI 1.3'3.5 vs. hepatitis B surface antigen-negative). The 5-year probability of LRD was low in those with F0/F1 fibrosis (sHR2.2%, 95%CI 1.7''2.9), but substantial in those withF2/F3 and F4 fibrosis (sHR 10.3%, 95% CI 7.6'13.5; and sHR 14.0%, 95% CI 10.3'18.3, respectively). Conclusion: Treatment with DAAs should be prioritized for those with at least F2 fibrosis. Early initiation of cART with the aim of avoiding low CD4 cell counts should be considered essential to decrease the risk of LRD and the need for HCV treatment.
AB - Background: Potent, less toxic, directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection promise to improve HCV cure rates among HIV/ HCV-co-infected individuals. However, the costs of treatment will necessitate prioritization of those at greatest risk of liver-related death (LRD) for therapy. This study aims to provide guidance on who should be prioritized for DAA treatment. Methods: Three thousand, nine hundred and forty-one HCV antibody-positive PSHREG and FIB-4 are names not acronyms (EuroSIDA) patients with follow-up after 1 January 2000 were included, with causes of death classified using Coding causes of Death in HIV (CoDe) methodology. Crude death rates, competing-risks Cox proportional- hazards models and cumulative incidence functions were used to describe factors associated with LRD. Results: LRD accounted for 145 of 670 (21.6%) deaths in the study population. LRD rates peaked in those aged 35'45 years, and occurred almost exclusively in those with at least F2 fibrosis at baseline. In adjustedCoxmodels, risk factors for LRDincluded F4 or F2/F3 fibrosis [sub-distribution hazard ratio (sHR) 6.3, 95%confidence interval (CI)4.1'9.6; andsHR2.5, 95%CI 1.5'4.2 vs. F0/F1, respectively), CD4 cell count (sHR 0.83, 95%CI 0.73'0.95 per doubling) and hepatitis B surface antigen-positive (sHR 2.2, 95% CI 1.3'3.5 vs. hepatitis B surface antigen-negative). The 5-year probability of LRD was low in those with F0/F1 fibrosis (sHR2.2%, 95%CI 1.7''2.9), but substantial in those withF2/F3 and F4 fibrosis (sHR 10.3%, 95% CI 7.6'13.5; and sHR 14.0%, 95% CI 10.3'18.3, respectively). Conclusion: Treatment with DAAs should be prioritized for those with at least F2 fibrosis. Early initiation of cART with the aim of avoiding low CD4 cell counts should be considered essential to decrease the risk of LRD and the need for HCV treatment.
KW - Causes of death
KW - Directly acting antivirals
KW - HIV/HCV co-infection
KW - Liver fibrosis
KW - Liver-related death
UR - http://www.scopus.com/inward/record.url?scp=84938990344&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000000674
DO - 10.1097/QAD.0000000000000674
M3 - Article
C2 - 25870984
AN - SCOPUS:84938990344
VL - 29
SP - 1205
EP - 1215
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 10
ER -
